EGFR and lung carcinoma: Though multidisciplinary therapeutic approaches toward NSCLC have improved survival and morbidity, the survival rates for advanced NSCLC remains dismal even with novel chemotherapy.[4] Inhibitors against epidermal growth factor receptor (EGFR) tyrosine kinase and antibodies against the ligand-binding domains of EGFR (such as cetuximab) that have come to clinical fruition produce only modest improvements in clinical outcomes.[5] However, there are multiple other molecular abnormalities in lung cancer yet unexplored.[6]